Paill Laboratorios

What Paill Laboratorios does

Paill Laboratorios (legal entity: GRUPO PAILL S.A. DE C.V.) is a privately held, 100% Salvadoran-capital pharmaceutical manufacturer founded in March 1993 in San Salvador, El Salvador. The company manufactures and commercializes approximately 400 pharmaceutical products organized across five main categories: over-the-counter medications (anchored by the flagship Sudagrip antigripal brand and Max multivitamins), generic medications, prescription medications, institutional medications, and an ophthalmological line. Core technology is a GMP-certified sterile manufacturing platform producing injectable solutions, oral medications, ophthalmic products, and sterile fluids; the company was the first pharmaceutical laboratory in El Salvador to obtain ISO 9001 certification and maintains a pharmacovigilance system mandated by pharmaceutical regulations.

The company generates revenue through direct pharmaceutical product sales to a network of exclusive country-level distributors operating across 8 Central American and Caribbean markets (El Salvador, Guatemala, Honduras, Nicaragua, Panama, Belize, Haiti, Dominican Republic), with additional revenue from direct sales to institutional customers including public hospitals, and from maquila (contract manufacturing) services offered to third-party pharmaceutical companies via a dedicated channel (maquilapaill.com). End customers span consumer/OTC buyers through retail pharmacies, prescription patients, and government healthcare institutions across the region. Headcount has grown from 6 collaborators at founding to over 1,000 employees by 2019, with women representing approximately 70% of the workforce.

Distribution is channel-partner-led, executed through appointed exclusive distributors per country (e.g., Helios S.A. in Guatemala and Nicaragua, CORFINAR and DRODISULA in Honduras, C.G. de Haseth in Panama, Distribuidora Nacional Farmacéutica and Laboratorios Antillados in Dominican Republic, PROPHALAB in Haiti). Direct institutional sales complement distribution, while engagement with healthcare professionals is driven through a proprietary webinars platform, participation in industry congresses such as EXPO-FARMA, and ongoing sports sponsorships of the Sudagrip brand. Notable milestones include recognition as the second-largest pharmaceutical exporter in El Salvador by the Asociación Salvadoreña de Industriales (ASI) in 2017-2018, COEXPORT's 'Exportador al Área Centroamericana 2017' and 'Mujer Exportadora 2019' awards, and Great Place to Work certification in Central America and the Caribbean in 2024. Leadership transitioned in December 2018 when Ana Carolina Escobar de Fiallos became the first woman appointed Executive Director by the Board of Shareholders; the founder, María Concepción Contreras, continues to be associated with the company's export legacy.

Name

Paill Laboratorios

Legal name

GRUPO PAILL S.A. DE C.V.

Website

https://paill.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Paill Laboratorios is a privately held, 100% Salvadoran-capital pharmaceutical manufacturer founded in 1993 in San Salvador, producing approximately 400 GMP-certified generic, prescription, OTC, institutional, and ophthalmological products distributed across 8 Central American and Caribbean countries through exclusive regional distributors, hospitals, and maquila contract manufacturing services.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Generic Hospital & Institutional Products (HLAIABAL), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF)

Keywords

• Pharmaceutical manufacturing
• Sterile injectable solutions
• Over-the-counter medications
• Generic prescription drugs
• Ophthalmic pharmaceutical products

Headquarters

HQ city

San Salvador

HQ country

El Salvador

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Manufacturing and commercializing pharmaceutical products including sterile products, OTC medications, generic medications, prescription medications, and ophthalmic line products. Revenue generated from direct sales to distributors, pharmacies, hospitals, and consumers.
2. Maquila Services: Contract manufacturing services (maquila) for third-party pharmaceutical products. The company offers manufacturing capabilities to other pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Paill Laboratorios manufactures and commercializes a portfolio of approximately 400 pharmaceutical products organized into five main categories: OTC medications (led by the flagship Sudagrip antigripal brand), generic medications, institutional medications, prescription medications, and an ophthalmological line (Iris brand). Production takes place in GMP-certified facilities in San Salvador covering sterile injectables, oral dosage forms, ophthalmic solutions, and other formats. The company also offers maquila (contract manufacturing) services to third-party pharmaceutical companies and distributes its products through an exclusive network of regional distributors across Central America and the Caribbean.

Product overview

Paill Laboratorios is a 100% Salvadoran pharmaceutical company that manufactures, produces, and commercializes pharmaceutical products. The portfolio comprises approximately 400 products organized into five main categories: OTC medications (over-the-counter), Generic medications, Institutional medications, Prescription medications, and an Ophthalmological line. Key brands include Sudagrip (flagship antigripal brand with capsules, syrups, powders, injectables, and lozenges) and Max Multivitamínicos. The company also provides maquila (contract manufacturing) services for third-party pharmaceutical products. The products range from cold/flu treatments, cardiovascular medications, pain management, anti-infectives, gastrointestinal treatments, neurological/psychiatric medications, hormonal contraceptives, to ophthalmological solutions. The company has presence across 8 Central American and Caribbean countries and operates under strict GMP (Good Manufacturing Practices) certification.

Differentiator

Problem solved

Functional benefit

Products and services

• Sudagrip Brand Line Leading over-the-counter antigripal brand offering capsules, syrups, powders, injectables, and lozenges for cold and flu symptom relief including pain, fever, congestion, and allergies, available for adult and pediatric consumers through pharmacies across Central America and the Caribbean.
• Max Multivitamínicos Multivitamin supplement brand supporting general health and wellness for individual consumers, sold through pharmacy retail channels.
• Iris Ophthalmological Line Ophthalmological line of prescription and OTC eye-care products including intraocular pressure reducers (Iris-Timol with Gellan Gum vehicle), aminoglycoside antibiotic eye drops (Iris-Tobra), tobramycin/dexamethasone combinations (Iris-Tobra D), artificial tears (Irislosa), anti-inflammatory medications (Iris-Dorzo), and miosis inhibitors for cataract surgery (Iris-Fenac), sold to pharmacies and institutional ophthalmology providers.
• Argesyl Forte Drinkable ampoule treatment for mental and physical fatigue, positioned as a recognized brand in the Salvadoran pharmaceutical market and sold through pharmacies as an OTC/consumer health product.
• Prescription Medication Portfolio Portfolio of prescription-only pharmaceutical products spanning cardiovascular, neurological, psychiatric, pain management, anti-infective, gastrointestinal, hormonal, respiratory, musculoskeletal, and urological therapeutic categories, sold through pharmacies (with prescription) and to institutional healthcare providers across Central America and the Caribbean.
• Generic Medication Portfolio Generic pharmaceutical products offered across multiple therapeutic categories at accessible price points, sold to pharmacies and institutional healthcare providers.
• Institutional Medication Portfolio Portfolio of institutional/hospital pharmaceutical products including sterile injectables, large-volume parenterals, electrolytes, rehydration solutions, anesthetic agents, and critical-care medications supplied directly to public and private hospitals.
• Maquila (Contract Manufacturing) Services Contract manufacturing (maquila) services offered to third-party pharmaceutical companies using Paill's GMP-certified facilities for sterile injectable, oral dosage form, and ophthalmic production.
• Mommex (mometasone furoate) Mommex, a mometasone furoate product, relaunched in a new presentation with regional representatives from Dominican Republic, Panama, and Honduras.

Quantifiable outcome

• Second largest pharmaceutical exporter in El Salvador
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature2 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• REDLIES (Red de Mujeres Líderes de Instituciones de Educación Superior)minorStrategic or Co-development Partner · 25 November 2021PAILL partnered with REDLIES to organize the second Orange Day event to raise awareness about violence against women.
• Mujeres Rosa InitiativeminorGTM or Marketing Partner · 11 October 2021PAILL joined the 'Mujeres Rosa' initiative led by ASAPRECAN (Asociación Salvadoreña para la Prevención del Cáncer) in conjunction with Connecta B2B and Revista Mercados & Tendencias.
• FUNDEMAS (Fundación Empresarial para la Acción Social)minorStrategic or Co-development Partner · 16 September 2021PAILL participates in the Week of Sustainability and RSE 2021 'Ecosystems for Sustainability 2021' organized by FUNDEMAS, held virtually October 11-14, 2021.
• ONU Mujeres (WEPs Campaign)minorStrategic or Co-development Partner · 19 July 2021PAILL joined the annual campaign promoted by ONU Mujeres for the promotion of the Principles for the Empowerment of Women (WEPs). The initiative promotes corporate actions to uphold women's rights.
• Alianza Fútbol ClubminorGTM or Marketing Partner · 30 July 2019Sudagrip brand signed sponsorship agreement with Alianza FC for Tournament Apertura 2019. Includes providing medication for player health, training on product benefits, and brand presence on all team communication portals.
• Holcim / GeocycleminorStrategic or Co-development Partner · 11 June 2019Partnership for co-processing of industrial and conventional waste. In 2018, PAILL delivered 10,513 kg of waste to Holcim/Geocycle for processing at temperatures exceeding 2,000 degrees Celsius. The Ministry of Environment monitors the entire process to ensure safe, non-polluting operation.
• Aldeas Infantiles SOS El SalvadorminorStrategic or Co-development Partner · 16 May 2019PAILL supports Aldeas Infantiles SOS through annual SOS Collection and Corporate Sponsorship program. Contributions fund the Family Strengthening Program and 34 community homes benefiting 3,800 children, adolescents, and teenagers. PAILL volunteers also bring joy to children at Aldeas Sonsonate.
• FEPADE (Fundación Empresarial para el Desarrollo Educativo)coreStrategic or Co-development Partner · 6 April 2018PAILL partners with FEPADE through their 'Edubecas' scholarship program to provide educational scholarships for children of PAILL employees. Since 2017, over 340 scholarships have been awarded with an investment of over $100,000. The program supports students with limited economic resources, good academic performance, and strong desire to succeed.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Laboratorios Gutis: Costa Rican pharmaceutical manufacturer with a comparable regional Central American footprint and a broad generics + branded OTC portfolio. Similar size band and business model to PAILL, making it the closest direct peer in the region.
• Laboratorios Stein: Costa Rica-headquartered pharmaceutical manufacturer with multi-country Central American distribution and a generics/OTC portfolio structurally similar to PAILL's. Operates at comparable scale across overlapping therapeutic categories.
• Laboratorios Lisan: Guatemalan pharmaceutical manufacturer serving Central America with branded generics and OTC products. Direct competitor in several of PAILL's core markets (Guatemala, Honduras) with a similar channel-driven distribution approach.
• Laboratorios Maver: Mexican pharmaceutical manufacturer with Central American market presence, focused on generics and specialty therapeutic lines. Direct competitor to PAILL across prescription and OTC generics in overlapping regional markets.
• Laboratorios López: Honduran pharmaceutical laboratory with a similar generics and OTC portfolio serving the Central American market. Closely comparable in size, geography, and channel mix to PAILL.

Broad incumbents

• Genfar: Multi-country Latin American generic pharmaceutical player owned by Sanofi, active across Central America and the Caribbean. Operates at materially larger scale than PAILL and competes directly in generics and selected OTC categories.
• Asofarma: Mexican/Latin American pharmaceutical company with broad specialty and generic portfolios sold across the region. Larger, more diversified incumbent competing with PAILL in prescription and institutional segments.
• Eurofarma: Brazil-headquartered multinational generic and branded pharmaceutical manufacturer with a broad Latin American footprint. Larger-scale incumbent that competes in generics and OTC across PAILL's markets.
• EMS Pharma: Brazil's largest domestic pharmaceutical company by units sold, with a generics-heavy portfolio expanding across Latin America. Comparable generics manufacturing model at materially larger scale.
• Bayer (Consumer Health): Global multinational with a large OTC and consumer health franchise (including cold/flu and analgesics) distributed across Central America and the Caribbean. Competes directly with PAILL's Sudagrip franchise and broader OTC portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Paill Laboratorios